翰思艾泰-B（03378）今日盘中大涨5.23%，引起了市场的广泛关注。
消息面上，公司开发的创新药注射用HX111已获中国国家药品监督管理局批准开展临床试验。HX111为首创OX40靶向抗体偶联药物(ADC)，临床前研究显示，OX40在若干恶性肿瘤中相较于正常组织呈过度表达，成为ADC的合适靶点。这一进展标志着公司在创新药研发领域取得重要突破，增强了市场对其未来增长潜力的信心。
翰思艾泰-B是一家专注于新一代免疫疗法开发的生物科技公司，此前已通过港股18A规则上市。HX111是公司继HX009及HX044两项双特异性抗体疗法后，推进至临床开发的第三个首创分子。公司表示将继续通过临床开发带来更多新颖药物，并最终推向市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.